PRICE NEGOTIATIONS IN CONTEXT OF EARLY BENEFIT ASSESSMENT IN GERMANY- IS A FLAT PRICING MODEL FOR NEW DRUGS ENFORCEABLE?

May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1996
https://www.valueinhealthjournal.com/article/S1098-3015(16)30281-9/fulltext
Section Title : Health Care Use & Policy Studies - Health Care Costs & Management
Section Order : 1114
First Page : A280
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30281-9&doi=10.1016/j.jval.2016.03.1996
HEOR Topics :
Tags :
Regions :